Objective: To develop and evaluate a deep learning model (AITO-PETCT-MP) for estimating malignancy probability in indeterminate pulmonary nodules using [18F]FDG
Objective: To summarize current knowledge on diagnostic trajectories in primary care for rheumatic musculoskeletal disorders (RMDs), identify knowledge gaps rel
Objective: To evaluate the patterns of cardiovascular involvement in patients with MIS-C associated with the SARS-CoV-2 Omicron variant and compare findings bet
Objective: To systematically compare the efficacy and safety of EUS-HGS alone versus EUS-HGAS in patients with unresectable malignant distal biliary obstruction
Malignant biliary obstruction (MBO) is primarily caused by pancreatic cancer and poses significant diagnostic and therapeutic challenges.
Endoscopic ultrasound-guided biliary drainage (EUS-BD) is an alternative to ERCP when traditional methods fail due to anatomical difficulties.
Hepaticogastrostomy with antegrade stenting (HGAS) combines two drainage routes, potentially improving outcomes compared to EUS-guided hepaticogastrostomy (HGS) alone.
The study aims to compare the efficacy and safety of EUS-HGS versus EUS-HGAS in patients with unresectable malignant distal biliary obstruction.
Primary outcomes include time to recurrent biliary obstruction (RBO) and need for reintervention, with secondary outcomes assessing technical and clinical success.
Objective: To approve new treatment options for adults with muscle-invasive bladder cancer who are candidates for cystectomy. Approach: Study Design: The KEYNOT
Objective: To report the FDA approval of subcutaneous isatuximab-irfc for multiple myeloma. Approach: Indications: Approved for use in combination with pomalido
The FDA approved subcutaneous isatuximab-irfc for three indications in adult patients with multiple myeloma.
Isatuximab-irfc is approved with pomalidomide and dexamethasone for patients with prior therapy including lenalidomide.
The drug is also approved with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
For newly diagnosed multiple myeloma patients not eligible for stem cell transplantation, it is approved with bortezomib, lenalidomide, and dexamethasone.
The recommended dose is 1,400 mg subcutaneously, with warnings for hypersensitivity, neutropenia, and other risks.
Objective: To evaluate whether mecobalamin can prevent complex regional pain syndrome type 1 (CRPS-1) following foot and ankle surgery. Approach: Study Design:
Objective: To advance care and community engagement for Huntington's disease under the leadership of Nicolas Phielipp, MD. Approach: Leadership: Nicolas Phielip
Objective: To evaluate the safety of discontinuing guideline-directed medical therapy (GDMT) in patients with atrial fibrillation after catheter ablation and re
Objective: To highlight federal actions by CMS and FDA that may impact physician practice in 2026. Approach: 2026 Medicare Physician Fee Schedule Final Rule: Fi
The 2026 Medicare Physician Fee Schedule final rule establishes separate conversion factors for qualifying and nonqualifying alternative payment model participants.
The 2026 Medicare Advantage and Part D final rule implements changes to prescription drug coverage and eliminates cost-sharing for certain adult vaccines.
CMS finalized a 2.6% update to payment rates for hospital outpatient services and ambulatory surgical centers meeting quality reporting requirements.
The FDA approved Foundayo, an oral GLP-1 therapy, for weight management in adults with obesity or overweight and related comorbid conditions.
The FDA cleared Dexcom’s Stelo Glucose Biosensor System for over-the-counter use by children aged 2 years and older who do not use insulin.
Objective: To compare the efficacy of Hyruan ONE, hylan G-F 20, and saline in reducing pain and improving function in patients with symptomatic knee osteoarthri
Objective: To introduce the JenaValve Trilogy Transcatheter Heart Valve System as a minimally invasive treatment option for patients with aortic regurgitation.
Objective: To discuss the rising rates of congenital syphilis in the US and the need for improved testing strategies to protect mothers and infants. Approach: C
Objective: To identify immune antibodies that appear earlier than current laboratory markers of Lyme disease and assess their potential in diagnosing acute and
Objective: To address the myopia epidemic and evaluate the limitations of conventional vision correction methods compared to surgical options, emphasizing the n
Objective: To investigate the association between neighborhood disadvantage and visual difficulty and blindness. Approach: Study Design: Cross-sectional study a
Objective: To explore the changing partnership models within the biopharma ecosystem. Approach: Gavin Murdoch, SVP of Commercial Strategy, Abzena: Discusses the